<DOC>
	<DOCNO>NCT01623778</DOCNO>
	<brief_summary>Along improvement accuracy detection HBV serological marker , optimization antiviral therapy patient chronic hepatitis B ( CHB ) infection become feasible . Currently , recommendation optimize treatment especially interferon therapy mainly base retrospective study , still lack prospective evidence . This study aim evaluate efficacy , safety pharmacoeconomics benefit 48 week optimize interferon therapy ( switch telbivudine plus adefovir dipivoxil ) HBeAg positive CHB inadequate response 24 week interferon treatment .</brief_summary>
	<brief_title>Optimization Antiviral Therapy Chronic HBV Infection</brief_title>
	<detailed_description>Patients inadequate response interferon therapy 24 week enrol study accept optimized therapy ( add ADV switch LDT ) 48weeks . All patient follow 48 week HBeAg seroconversion HBV DNA level observe . Safety economic effect two optimized therapy method also observe .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>patient receive Peg interferon α2a inadequate response 24 week ( HBeAg titer ≥ 100Paul Ehrlich Institute Unit ( PEIU ) /ml HBV DNA ≥ 5.0 Log copies/ml HBV DNA titer decline &lt; 1 Log copies/ml ) enrol study . decompensated cirrhosis , hepatitis C , hepatitis D human immunodeficiency virus ( HIV ) coinfection , hepatocellular carcinoma tumor history severe hepatitis , system disease , history cardiopulmonary disease , thyroid disorder , immune system disorder , epilepsy mental illness ( severe depression ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>HBeAg seroconversion</keyword>
	<keyword>Peginterferon alfa-2a</keyword>
	<keyword>chronic hepatitis B ( CHB</keyword>
	<keyword>Optimal therapy</keyword>
	<keyword>Response guild treatment ( RGT ) ;</keyword>
</DOC>